Seres Therapeutics launched VOWST for recurrent C. difficile infection in early June, in partnership with Nestle Health. VOWST represents a significant improvement over current standard of care.

Please provide your email address to receive an email when new articles are posted on . “The availability of a fecal microbiota product that can be taken orally is a significant step forward in ...

BRIDGEWATER, N.J., June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which ...

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy, an innovator and leader in the specialty pharmacy industry, has been selected as one of only two pharmacies nationally selected by Aimmune ...

ELK GROVE VILLAGE, Ill., June 22, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that Aimmune Therapeutics has selected it as a limited distribution partner for VOWST™ (fecal ...

Scanning electron micrograph (SEM) of bacteria cultured from a sample of human feces. Supermarket shelves are full of largely unregulated probiotics that aim to keep gut bacteria in balance. With its ...

The price you pay for Vowst may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost of ...

Seres Therapeutics has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with ...

Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high-resolution functional biological understanding ...